| Saif Alrabadi, MD | |
|
13575 W Mcdowell Rd, Goodyear, AZ 85395-2604 | |
| (623) 536-9911 | |
| Not Available |
| Full Name | Saif Alrabadi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 13575 W Mcdowell Rd, Goodyear, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518413871 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 65551 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abrazo West Campus | Goodyear, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Leading Healthcare, Pllc | 1850652496 | 22 |
| Med-cure Internal Medicine, Plc | 2668522665 | 24 |
News Archive
More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.
› Verified 1 days ago
| Entity Name | Med-cure Internal Medicine, Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831323708 PECOS PAC ID: 2668522665 Enrollment ID: O20090612000514 |
News Archive
More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.
› Verified 1 days ago
| Entity Name | Cogent Healthcare Of Arizona Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568758266 PECOS PAC ID: 0648441006 Enrollment ID: O20110915000843 |
News Archive
More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.
› Verified 1 days ago
| Entity Name | Leading Healthcare, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356853691 PECOS PAC ID: 1850652496 Enrollment ID: O20180222002817 |
News Archive
More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Saif Alrabadi, MD Po Box 2510, Mesa, AZ 85214-2510 Ph: (928) 955-2033 | Saif Alrabadi, MD 13575 W Mcdowell Rd, Goodyear, AZ 85395-2604 Ph: (623) 536-9911 |
News Archive
More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.
Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon's consulting and management organization with clinical expertise in the development of cardiovascular products and trials.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.
› Verified 1 days ago
Dr. Stephen F Lynch, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14200 W Celebrate Life Way, Goodyear, AZ 85338 Phone: 623-207-3024 | |
Robyn Fossey, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1325 N Litchfield Rd Ste 110, Goodyear, AZ 85395 Phone: 623-935-9494 | |
Hui Gao, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13677 W Mcdowell Rd, Goodyear, AZ 85395 Phone: 623-882-1500 | |
Melia Kay Cox, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13471 W Cornerstone Blvd, Goodyear, AZ 85395 Phone: 877-809-5092 Fax: 623-583-3007 | |
Bonte Gbemudu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 13471 W Cornerstone Blvd, Goodyear, AZ 85395 Phone: 877-809-5092 Fax: 623-213-8808 | |
Dr. Nathan Andrew Tholl, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9780 S Estrella Pkwy, Goodyear, AZ 85338 Phone: 623-474-8101 | |
Amanda Janulis, FNP-C Family Medicine Medicare: Medicare Enrolled Practice Location: 18321 W Coolidge St, Goodyear, AZ 85395 Phone: 623-628-0311 |